Keywords
How to Cite
Abstract
Below we would like to clarify the issues that arise in practice in patients who are prescribed micronized progesterone in obstetrics and gynecology.
Micronized progesterone has been widely used over the past 40 years in different countries of the world as the main factor of preserving the fetus in early and late pregnancy. The risk of miscarriage is one of urgent problems that are growing day by day. Planning the first pregnancy after 30-35 years, an increase in number of pregnancies after assisted reproductive technologies, the negative impact of environmental factors, stress - all these factors increase the complication of pregnancy and, first of all, the number of spontaneous abortions.
References
Coomarasamy A., Helen Williams H., Truchanowicz E. et al. A randomized trial of progesterone in women with recurrent miscarriages. N Engl J Med. 2015;373(22):2141–8
Manukhin I.B., Dobrokhotova E.Yu., Kuleshchov V.M. et al. Treatment of threatened miscarriage with micronized progesterone and dydrogesterone (results of a multicenter, open, prospective comparative non-interventional study). Problems of reproduction. 2018;24(3):34–42. 3. Coomarasamy A., Devall A. J., Cheed V. et al. A randomized trial of progesterone in women with bleeding in early pregnancy. N Engl J Med. 2019;380(19):1815–24.
Order of the Government of the Russian Federation of October 12, 2019 No. 2406-r. M., 2019. 261 p. 5. Raghupathya R, Al-Mutawaa E, Al-Azemib M et al. Progesterone-induced blocking factor (PIBF) modulates cytokine production by lymphocytes from women with recurrent miscarriage or preterm delivery. J Reprod Immunol 2009; 80 (1–2): 91–9.
Milewich L., Gant N.F., Schwarz B.E., Chen G.T., Macdonald P.C.
Initiation of human parturition. IX. Progesterone metabolism by placentas of early and late human gestation // Obstet. Gynecol. 1978. Vol.51, №3. Р.278–280. 7. Milewich L., Gant N.F., Schwarz B.E., Chen G.T., Mac Donald P.C. 5 alpha-reductase activity in human placenta // Am. J. Obstet. Gynecol. 1979. Vol.133, №6. Р.611– 617.
Junkermann H., Runnebaum B., Lisboa B.P. New progesterone metabolites in human myometrium // Steroids. 1977. Vol.30, №1. Р.1–14. 9. Junkermann H., Runnebaum B., Lisboa B.P. New progesterone metabolites in human myometrium // Steroids. 1977. Vol.30, №1. Р.1–14. 10. Milewich L., Gant N.F., Schwarz B.E., Prough R.A., Chen G.T., Athey B., MacDonald P.C. Initiation of human parturition. VI. Identification and quantification of progesterone metabolites produced by the components of human fetal membranes // J. Clin. Endocrinol. Metab. 1977. Vol.45, №3. P.400–411. 11. Meis P.J. 17 hydroxyprogesterone for the prevention of preterm delivery // Obstet. Gynecol. 2005. Vol.105, №5(Pt1). Р.1128–1135. 12. Merlob P., Stahl B., Klinger G. 17α Hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth // Reprod. Toxicol. 2012. Vol.33, №1. Р.15–
Progesterone-treated limphocytes of healthy pregnant women release a factor inhibiting cytotoxicity and prostaglandin synthesis / Szekeres-Bartho J. [et al.] // Am. J. Reprod. Immunol. — 1985.— Vol.9. — P.15–19. 14. Doctor of Medical Sciences, Prof. I.B. MANUKHIN1, Doctor of Medical Sciences, Prof. Yu.E. DOBROKHOTOVA2, Doctor of Medical Sciences, Prof.
V.M. KULESHOV3, Doctor of Medical Sciences, Prof. V.B. TSKHAI4, MD, prof.
N.I. TAPILSKAYA5, Doctor of Medical Sciences, Prof. I.E.ROGOZHINA, Doctor of Medical Sciences, Prof. V.G. VOLKOV7, Doctor of Medical Sciences, Prof. AND ABOUT. BUSHTYREVA8, Ph.D. M.I. BAZINA
This work is licensed under a Creative Commons Attribution 4.0 International License.